Analysis of Nevirapine Resistance Mutations in Cloned HIV Type 1 Variants from HIV-Infected Ugandan Infants Using a Single-Step Amplification-Sequencing Method (AmpliSeq)
Restricted accessResearch articleFirst published online September, 2008
Analysis of Nevirapine Resistance Mutations in Cloned HIV Type 1 Variants from HIV-Infected Ugandan Infants Using a Single-Step Amplification-Sequencing Method (AmpliSeq)
We analyzed the genetic linkage of nevirapine (NVP) resistance mutations and the genetic complexity of HIV-1 variants in Ugandan infants who were HIV infected despite single dose (SD) prophylaxis. Plasma samples were obtained from six HIV-infected infants who had two or more NVP resistance mutations detected by population sequencing (ViroSeq). ViroSeq PCR products were cloned and transformed, and a single-step amplification-sequencing reaction (AmpliSeq) was used to analyze NVP resistance mutations in cloned HIV-1 variants directly from bacterial colonies. Fifty clones were analyzed for each infant sample. This analysis revealed numerous NVP resistance mutations not detected by population sequencing, genetically linked NVP resistance mutations, and a high degree of genetic complexity at codons that influence NVP susceptibility.
Get full access to this article
View all access options for this article.
References
1.
McConnellMS, StringerJS, KourtisAP, WeidlePJ, EshlemanSH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: Does development of resistance matter?Am J Obstet Gynecol, 2007; 197:S56–63.
2.
FlysTS, DonnellD, MwathaAet al.Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis, 2007; 195:711–715.
3.
JohnsonJ, LiJF, WeiXet al.Low-frequency mutations substantially increase the prevalence of transmitted drug resistance, greatly strengthen the relationship between resistance mutations, virologic failure. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28, 2007Abstract #639.
4.
EllisGM, MahalanabisM, BeckIAet al.Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol, 2004; 42:3670–3674.
5.
PalmerS, BoltzV, MartinsonNet al.Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA, 2006; 103:7094–7099.
6.
EshlemanSH, JonesD, FlysT, PetrauskeneO, JacksonJB. Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping System. Biotechniques, 2003; 35:614–618620, 622.
7.
PalmerS, KearneyM, MaldarelliFet al.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol, 2005; 43:406–413.
8.
HoffmannC, MinkahN, LeipzigJet al.DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res, 2007; 35:e91.
9.
CaiF, ChenH, HicksCB, BartlettJA, ZhuJ, GaoF. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods, 2007; 4:123–125.
10.
MurphyKM, BergKD, EshlemanJR. Sequencing of genomic DNA by combined amplification and cycle sequencing reaction. Clin Chem, 2005; 51:35–39.
11.
GuayLA, MusokeP, FlemingTet al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 1999; 354:795–802.
12.
JacksonJB, MusokeP, FlemingTet al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet, 2003; 362:859–868.
13.
McConnellMS, BakakiP, EureCet al.Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies, Uganda. J Acquir Immune Defic Syndr, 2007; 46:291–296.
14.
HallTA. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser, 1999; 41:95–98.
15.
Stanford University: Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu/cgi-bin/NNR-TIResiNote.cgi. 0408.
16.
ParkinNT, GuptaS, ChappeyC, PetropoulosCJ. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother, 2006; 50:351–354.
